Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of the Multi-Drug Resistance Protein Modulating Agent Sulindac in Combination With Epirubicin in Patients With Advanced Melanoma

NCT00755976 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT00755976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00755976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of the Multi-Drug Resistance Protein Modulating Agent Sulindac in Combination With Epirubicin in Patients With Advanced Melanoma
Lead sponsor
Cancer Trials Ireland
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2007
Completion date
May 31, 2010
Enrollment
32 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)